Chanelle founder invests €100k in Redesdale Group
Michael Burke has taken a stake in a firm that will seek to acquire or invest in early stage food and wellness businesses
Michael Burke, the founder of Chanelle Pharmaceuticals, has joined veteran financier John Conroy’s Redesdale Group as a shareholder.
Set up by Conroy, the Merrion Capital founder, and formerly called Acton Health & Wellness Fund, Redesdale Group is expected to close an initial funding round in the region of €25 million later this quarter, sources familiar with the venture said.
Burke has invested in the region of €100,000 as part of his involvement in...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
‘I always had entrepreneurial ambitions and this was first-hand evidence of an unmet need’
Neuromod’s chief executive Dr Ross O’Neill says his company’s Lenire device, which aids tinnitus sufferers, can establish a sizeable market — particularly in the US among military veterans
PM Group reports 30% profits increase and announces 200 new jobs in Ireland
The project delivery firm said that pharmaceutical projects accounted for almost two-thirds of its overall revenue for 2020, which rose to almost €400 million
Neuromod Devices to double Irish headcount within next year
The medtech company, which specialises in neuromodulation devices indicated for the treatment of tinnitus, said it hopes to roll out its product in European countries such as France, Spain and the Netherlands
Malin shareholders in line for windfall after €119 million cash boost
Dublin-based biotech investment fund said €45 million of the proceeds from the sale will be used to repay a European Investment Bank loan, with the remaining cash to be returned to shareholders later this year